tracon
announces
fda
orphan
drug
designation
malignant
glioma
including
glioblastoma
san
diego
globe
newswire
tracon
pharmaceuticals
nasdaq
tcon
clinical
stage
biopharmaceutical
company
focused
development
commercialization
novel
targeted
cancer
therapeutics
utilizing
cost
efficient
product
development
platform
partner
companies
develop
commercialize
innovative
products
today
announced
food
drug
administration
fda
granted
orphan
drug
designation
treatment
patients
malignant
glioma
including
glioblastoma
gbm
small
molecule
inhibitor
dna
base
excision
repair
pathway
studied
multiple
phase
phase
clinical
trials
sponsored
national
cancer
institute
cooperative
research
development
agreement
crada
evaluated
phase
trial
combination
temodar
chemotherapy
patients
progressive
recurrent
gbm
progressed
following
temodar
external
beam
radiotherapy
extended
survival
observed
two
patients
two
years
demonstrated
activation
dna
base
excision
repair
pathway
demonstrated
hyperactivation
dna
damage
response
genes
also
evaluated
combination
chemotherapy
external
beam
radiotherapy
separate
phase
study
patients
newly
diagnosed
cell
cell
lung
cancer
resulted
response
radiographic
evaluation
criteria
solid
tumors
recist
patients
including
three
patients
complete
response
treatment
orphan
drug
designation
underscores
high
level
unmet
medical
need
patients
malignant
glioma
supports
potential
indication
based
previously
reported
data
demonstrating
prolonged
survival
patients
retreated
temodar
combined
said
james
freddo
chief
medical
officer
tracon
remain
committed
developing
collaboration
national
cancer
institute
believe
data
generated
date
provide
rationale
study
combination
temodar
radiotherapy
newly
diagnosed
patients
malignant
fda
orphan
drug
designation
program
provides
orphan
status
drugs
biologics
developed
address
rare
diseases
disorders
affect
fewer
people
orphan
designation
tracon
qualifies
various
incentives
respect
treatment
glioblastoma
including
tax
credits
qualified
clinical
trials
seven
years
market
exclusivity
upon
receipt
regulatory
approval
methoxyamine
novel
small
molecule
inhibitor
dna
base
excision
repair
pathway
pathway
causes
resistance
alkylating
antimetabolite
chemotherapeutics
currently
studied
multiple
phase
phase
clinical
trials
sponsored
national
cancer
institute
cooperative
research
development
agreement
crada
information
clinical
trials
please
visit
tracon
website
malignant
glioma
gbm
gbm
also
called
glioblastoma
malignant
glioma
develops
glial
cells
astrocytes
oligodendrocytes
support
health
nerve
cells
within
brain
gbm
invasive
type
glial
tumors
rapidly
growing
commonly
spreading
nearby
brain
tissue
national
cancer
institute
estimates
approximately
adults
men
women
diagnosed
brain
nervous
system
cancer
annually
approximately
diagnoses
result
death
gbm
incidence
two
three
per
adults
per
year
accounts
percent
primary
brain
tumors
tracon
tracon
develops
targeted
therapies
cancer
utilizing
capital
efficient
cro
independent
product
development
platform
company
pipeline
includes
envafolimab
subcutaneous
antibody
developed
treatment
sarcoma
registrational
trial
phase
ready
small
molecule
drug
candidate
treatment
prostate
cancer
phase
small
molecule
drug
candidate
development
treatment
lung
cancer
glioblastoma
phase
antibody
development
treatment
advanced
solid
tumors
tracon
actively
seeking
additional
corporate
partnerships
whereby
leads
regulatory
clinical
development
shares
cost
risk
clinical
development
leads
commercialization
partnerships
tracon
believes
serve
solution
companies
without
clinical
commercial
capabilities
learn
tracon
product
pipeline
visit
tracon
website
statements
statements
made
press
release
regarding
matters
historical
facts
statements
within
meaning
private
securities
litigation
reform
act
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
statements
include
limited
statements
regarding
tracon
national
cancer
institute
plans
develop
product
candidates
potential
benefits
orphan
drug
designation
expectations
regarding
clinical
trials
development
regulatory
plans
potential
benefits
tracon
business
development
strategy
goals
risks
could
cause
actual
results
differ
expressed
statements
include
risks
associated
clinical
development
whether
tracon
others
able
complete
initiate
clinical
trials
tracon
expected
timelines
including
due
risks
associated
pandemic
pandemics
fact
future
preclinical
studies
clinical
trials
may
successful
otherwise
consistent
results
prior
studies
fact
tracon
limited
control
whether
third
party
collaborators
complete
trials
initiate
additional
trials
seek
regulatory
approval
tracon
product
candidates
fact
tracon
collaboration
agreements
subject
early
termination
whether
tracon
able
enter
additional
collaboration
agreements
favorable
terms
whether
expected
benefits
orphan
drug
designation
ultimately
realized
including
due
potential
loss
orphan
drug
designation
development
competing
products
potential
changes
regulatory
requirements
united
states
foreign
countries
tracon
reliance
third
parties
development
product
candidates
including
conduct
clinical
trials
manufacture
product
candidates
whether
tracon
able
obtain
additional
financing
risks
described
tracon
filings
securities
exchange
commission
heading
risk
factors
statements
contained
press
release
speak
date
made
based
management
assumptions
estimates
date
tracon
undertakes
obligation
update
statements
reflect
events
occur
circumstances
exist
date
made
company
contact
investor
contact
mark
wiggins
brian
ritchie
chief
business
officer
lifesci
advisors
llc
mwiggins
britchie
